EP1700947B1 - Fabric with active principles and relevant recharging method of the active principles - Google Patents

Fabric with active principles and relevant recharging method of the active principles Download PDF

Info

Publication number
EP1700947B1
EP1700947B1 EP06004931A EP06004931A EP1700947B1 EP 1700947 B1 EP1700947 B1 EP 1700947B1 EP 06004931 A EP06004931 A EP 06004931A EP 06004931 A EP06004931 A EP 06004931A EP 1700947 B1 EP1700947 B1 EP 1700947B1
Authority
EP
European Patent Office
Prior art keywords
fabric
active principles
hexapeptide
anyone
recharging
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP06004931A
Other languages
German (de)
French (fr)
Other versions
EP1700947A3 (en
EP1700947A2 (en
Inventor
Morena Restani
Lucio Lenzi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to DE602006008679T priority Critical patent/DE602006008679D1/en
Publication of EP1700947A2 publication Critical patent/EP1700947A2/en
Publication of EP1700947A3 publication Critical patent/EP1700947A3/en
Application granted granted Critical
Publication of EP1700947B1 publication Critical patent/EP1700947B1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • DTEXTILES; PAPER
    • D06TREATMENT OF TEXTILES OR THE LIKE; LAUNDERING; FLEXIBLE MATERIALS NOT OTHERWISE PROVIDED FOR
    • D06MTREATMENT, NOT PROVIDED FOR ELSEWHERE IN CLASS D06, OF FIBRES, THREADS, YARNS, FABRICS, FEATHERS OR FIBROUS GOODS MADE FROM SUCH MATERIALS
    • D06M15/00Treating fibres, threads, yarns, fabrics, or fibrous goods made from such materials, with macromolecular compounds; Such treatment combined with mechanical treatment
    • D06M15/01Treating fibres, threads, yarns, fabrics, or fibrous goods made from such materials, with macromolecular compounds; Such treatment combined with mechanical treatment with natural macromolecular compounds or derivatives thereof
    • D06M15/15Proteins or derivatives thereof
    • DTEXTILES; PAPER
    • D06TREATMENT OF TEXTILES OR THE LIKE; LAUNDERING; FLEXIBLE MATERIALS NOT OTHERWISE PROVIDED FOR
    • D06MTREATMENT, NOT PROVIDED FOR ELSEWHERE IN CLASS D06, OF FIBRES, THREADS, YARNS, FABRICS, FEATHERS OR FIBROUS GOODS MADE FROM SUCH MATERIALS
    • D06M23/00Treatment of fibres, threads, yarns, fabrics or fibrous goods made from such materials, characterised by the process
    • D06M23/12Processes in which the treating agent is incorporated in microcapsules
    • DTEXTILES; PAPER
    • D06TREATMENT OF TEXTILES OR THE LIKE; LAUNDERING; FLEXIBLE MATERIALS NOT OTHERWISE PROVIDED FOR
    • D06MTREATMENT, NOT PROVIDED FOR ELSEWHERE IN CLASS D06, OF FIBRES, THREADS, YARNS, FABRICS, FEATHERS OR FIBROUS GOODS MADE FROM SUCH MATERIALS
    • D06M2101/00Chemical constitution of the fibres, threads, yarns, fabrics or fibrous goods made from such materials, to be treated
    • D06M2101/16Synthetic fibres, other than mineral fibres
    • D06M2101/30Synthetic polymers consisting of macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
    • D06M2101/38Polyurethanes

Definitions

  • the present invention refers to a fabric with active principles and to a recharging method of said principles having the main aim to prevent and/or to give the first cures to the diabetic foot.
  • the problems to the feet caused to ulcers, accidental injuries, micro-traumas, wounds also light, callosity and infections.
  • the persons with these pathologies have a reduced flux of blond in the inferior arts, in particular from the knee to the foot, owing to a stricture of the arteries.
  • the diabetes gives a progressive destruction of the nerves that arrive to the foot and to a skin degeneration, that becomes dry and inflexible, so easy to be subjected to wounds.
  • the concomitance of these events determines infections often careless and minimal realized to the diabetic patient, this due also to a minor sensibility of the nervous terminations of the foot.
  • the degenerative forms created to a light wound are, owing to the complications given to the metabolic, circulatory and neurological alterations, not to disregard as they easily evolve in serious pathologies, unfortunately favourite to long times for healing the wounds in the diabetic patient, with consequent increasing of risk of bacterial, viral and mycotic infections.
  • the complications of a normal disregarded ulceration are one of the more frequent causes of admission to hospital for this pathology.
  • the non-prevention and non-care of that known as diabetic foot determines the claudication and, in the grave cases, the amputation of the art.
  • a consistent percentage of diabetic persons are subjected to ulcerations to the feet that prolong in the time can grow worse.
  • To have an idea of the problem are cited the data of the Health World Organization where are counted in one hundred and twenty million the diabetic persons in year 1996 and it is estimated in three hundred million the number of diabetic persons in year 2025, where on an average the 15% will have ulcerations to the feet with complications.
  • Always from the cited sources are known data that counted that for one hundred diabetic patients with amputations eighty-four have had as cause of the amputation an ulceration to a foot grows worse in time.
  • the invention creates a fabric, for specific application in this pathology, impregnated with substances with synergetic action and gradual release, and a recharging method of said active substances when these have lost their efficacy in time.
  • the recharging of the active principles to the fabric permits a reusing of the specific fabric and it permits to have a set of clothes with controlled release of the active substances.
  • the invention consists of a fabric 1 in lycra fibres and micro-fibres (known with the trade "meryl"), in variable percentages for application of this kind, that in actuation has the form of stocking 2, pantyhose 3, sock 4, winding bandage with closed border 5, bandage or plaster 6.
  • This type of fabric has the characteristic to have fibres with minor or equal subtlety to ten micrometer. So the fibres of this fabric are of inferior diameter to that of the silk, that have a subtlety of the fibres of twelve micrometer of the cotton with subtlety of the fibres of thirteen and half micrometer of the cashmere with fibres diameter dimension of fifteen micrometer and of the wool with fibres diameter dimension of seventeen micrometer.
  • the application of this characteristic of the invention is of big importance for the diabetic foot such as more the thread is thin minor are the damages to abrasion of the fabric onto the skin. So an extremely smooth fabric is obtained that no creates micro-abrasions onto the inelastic skin and dry of the diabetic patient.
  • the fabric 1 is provided in the woof of thin silver yarns 7 with function anti-bacteric and bacteriostatic.
  • pantyhose 3, sock 4 has a sewing with flat folding 8 in the anterior part of the stocking, imperceptible to the touch.
  • the fabric 1 moreover, ha elastic property (elasticity of 99-100%) so to not obstruct the venous flux, to not worsening the occlusive peripheral arterypatia and to favourite the local microcirculation.
  • it has capacity of umidity absorption, low rate of water retention and, differently to the natural fibres, quick time of drying.
  • glycoprotein (9) (pseudoalteromonos ferment extract, known with the trade "antarcticine") synthesized to a bacteria (pseudoalteromanas antartica NF3) of the species Gram-negative, with composition of the fat acids and to the proteinic outline typical of the alteromonas family.
  • This substance during the cellular growth produces a glycoprotein exopolymer composed of the 76-86% of proteins and to 8-14% of sugar, in base of the used means.
  • This active substance have had use, previous to the invention, like a cosmetic humectant and emollient ingredient and like a substance with crioprotective property.
  • Said active principle of new and original application in the treatment of the diabetic foot, has important property that opposed the dryness of the skin typical of the diabetic patient. It gives, infact, the coesion between the spinous and germinativum stratum favouring the madding and the folding of the interkeratociti liquids, so as estimated through the compression studies of the isotherms and of the multilayer of the Langmuir balance.
  • said substance stimulates the growth of the human skin fibroblast in the tests in vitro without the growth of the keratinociti, so acting onto the micro-ulcerations of the skin to their first turning up and onto all the cute surface, from the knee to the foot.
  • the active principle given to the cited substance increases the formation of elastin and of collagen type I and type IV with increasing of the cute hydration of at least the 45% in the twelve subsequent hours in comparison with a sample of skin not treated or treated with cream with the only placebo effect.
  • This substance is inserted in the wet fabric in a quantity of at least 1 mg/ml.
  • an exapeptide (10) from the alpha chain (known with trade "serilesine”).
  • This peptide increases the adhesion of the cells, favours the cellular proliferation and betters the microcirculation such as it favours the angiogenesis.
  • This active substance is added to the wet fabric 1 in quantity at least of 0,05 mg/ml. Also this last substance is never previous used for the use in pathology such that of the diabetic foot. Both these substances are previous used in the cosmetic field. So they do not present toxicity problems and they are not to be considered drugs to be prescribed with prescription.
  • the fabric 1 is then washed in water at 50°C. Ending this working the water is discharged and the fabric is wet with clean water to which is added a mordanting assistant 12, the Nylofixam PM (sold by Clariant) that has the function to bound the substances contained in the microcapsules 11 to the aminic group of the fabric 1, by means of the polarization that favours the union between the fabric 1 and the substances 9 and 10 into the microcapsules.
  • the fixer 12 is then added in proportion of 4% of the weight of the fabric 1 to treat. Then are introduced in the bath the microcapsules 11 in the dose previous described and in total quantity of the 6% of the weight of the fabric. After ten minutes is added a cationic product 13, i.e.
  • softenol 70 (sold by Lautex) that contributes also it to bound the microcapsules 11 with the fabric 1.
  • the "lautex” is added in percentage of 2% of the weight of the fabric. After ninety minutes the bath is let out and the fabric 1 is centrifuged and dry, ready to be used.
  • the microcapsules 11 and the fixers 12 and 13 to the fabric 1 are sold in pre-dosed packaging, to can use the stocking 2, the pantyhose 3, the sock 4, the winding bandage 5, the bandage or plaster 6.
  • To actuate the recharging of the active substances 9 and 10 to the fabric 1 for domestic three grams of substances 9 and 10 in microcapsules 11 are brought and they are dissolved into 300-500 ml.
  • the simple application of a cream with active principles does not reach the useful results for the diabetic foot pathology such as the results obtained with the invention such as the friction of the foot with the conventional pantyhose creates, during the walk, frictions that take off the cream instead of makes it to absorb to the skin of the foot and neither the occlusive bandages with cream and gauzes are not to be used if no with the patient in bed.
  • the invention is so to be used in the daily without constraints and/or changing to the style of life of the patient.
  • the invention in the application in the form of application also winding bandage 5, cicatrizant bandage or plaster 6 have application also remedy for the bedsores and/or light wounds..
  • FIG. 1 is view of an example of production like a stocking.
  • Figure 2 is view of an application like a stock.
  • Figure 3 is view of the version like a pantyhose.
  • Figure 4 is view of the version of winding bandage with closed profile.
  • Figure 5 is view of the version of bandage or plaster.
  • sheet 2 are illustrated some sequences of the recharging phase of the active principles of the invention.
  • figure 6 is view of the immersion phase.
  • Figure 7 is view of the invention soaks in water with the active principles.

Landscapes

  • Engineering & Computer Science (AREA)
  • Textile Engineering (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Detergent Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

The fabric consists of lycra fibres and microfibres and it has long the fibres a glycoprotein (9) and an exapeptide (10). The woof of this fabric and the active principles given to these two substances (9,10) prevent and/or give the first cures to the diabetic foot.

Description

  • The present invention refers to a fabric with active principles and to a recharging method of said principles having the main aim to prevent and/or to give the first cures to the diabetic foot. Between the diabetes complications are known the problems to the feet caused to ulcers, accidental injuries, micro-traumas, wounds also light, callosity and infections. Are known the grave damages and the risks of grafting of important complications from light wounds in the diabetic patient. The persons with these pathologies have a reduced flux of blond in the inferior arts, in particular from the knee to the foot, owing to a stricture of the arteries. Moreover, the diabetes gives a progressive destruction of the nerves that arrive to the foot and to a skin degeneration, that becomes dry and inflexible, so easy to be subjected to wounds. The concomitance of these events determines infections often careless and minimal realized to the diabetic patient, this due also to a minor sensibility of the nervous terminations of the foot. The degenerative forms created to a light wound are, owing to the complications given to the metabolic, circulatory and neurological alterations, not to disregard as they easily evolve in serious pathologies, unfortunately favourite to long times for healing the wounds in the diabetic patient, with consequent increasing of risk of bacterial, viral and mycotic infections. The complications of a normal disregarded ulceration are one of the more frequent causes of admission to hospital for this pathology. The non-prevention and non-care of that known as diabetic foot determines the claudication and, in the grave cases, the amputation of the art. A consistent percentage of diabetic persons are subjected to ulcerations to the feet that prolong in the time can grow worse. To have an idea of the problem are cited the data of the Health World Organization where are counted in one hundred and twenty million the diabetic persons in year 1996 and it is estimated in three hundred million the number of diabetic persons in year 2025, where on an average the 15% will have ulcerations to the feet with complications. Always from the cited sources are known data that counted that for one hundred diabetic patients with amputations eighty-four have had as cause of the amputation an ulceration to a foot grows worse in time. Moreover, over the 50% of all the amputations of the lower limbs regards diabetic patients. Currently are not known local preventive applications to be constantly used to prevent, cure or reinforce the defences of the foot of the diabetic patient so to avoid the complications previous described. The sole forms of prevention in this delicate sector are given prevalently based onto mode of behaviour as the careful test of the food, the sanitary education for observation of hygienic rules, the using of correct shoes and the application of topical remedy at the appearing of the first ulcerations. The invention, instead, realizes a therapeutic remedy able to prevent the formation of ulcerations and to favourite the recovery of wounds eventually formed. The invention creates a fabric, for specific application in this pathology, impregnated with substances with synergetic action and gradual release, and a recharging method of said active substances when these have lost their efficacy in time. The recharging of the active principles to the fabric permits a reusing of the specific fabric and it permits to have a set of clothes with controlled release of the active substances. The invention consists of a fabric 1 in lycra fibres and micro-fibres (known with the trade "meryl"), in variable percentages for application of this kind, that in actuation has the form of stocking 2, pantyhose 3, sock 4, winding bandage with closed border 5, bandage or plaster 6. This type of fabric, with new application for the specific pathology of the diabetic foot, has the characteristic to have fibres with minor or equal subtlety to ten micrometer. So the fibres of this fabric are of inferior diameter to that of the silk, that have a subtlety of the fibres of twelve micrometer of the cotton with subtlety of the fibres of thirteen and half micrometer of the cashmere with fibres diameter dimension of fifteen micrometer and of the wool with fibres diameter dimension of seventeen micrometer. The application of this characteristic of the invention is of big importance for the diabetic foot such as more the thread is thin minor are the damages to abrasion of the fabric onto the skin. So an extremely smooth fabric is obtained that no creates micro-abrasions onto the inelastic skin and dry of the diabetic patient. In other embodiment of the invention the fabric 1 is provided in the woof of thin silver yarns 7 with function anti-bacteric and bacteriostatic. To avoid grazes from sewing the invention, in the form of the stocking 2, pantyhose 3, sock 4, has a sewing with flat folding 8 in the anterior part of the stocking, imperceptible to the touch. The fabric 1, moreover, ha elastic property (elasticity of 99-100%) so to not obstruct the venous flux, to not worsening the occlusive peripheral arterypatia and to favourite the local microcirculation. Unlike to the other synthetic fibres, moreover, it has capacity of umidity absorption, low rate of water retention and, differently to the natural fibres, quick time of drying. These characteristic have like resulting capacity to oppose the formation of fungus and to limit the bacteric growth. To the fabric 1 are then added active substances with application method to the fabric and recharging method of new conception. To the fabric 1 is bound a glycoprotein (9) (pseudoalteromonos ferment extract, known with the trade "antarcticine") synthesized to a bacteria (pseudoalteromanas antartica NF3) of the species Gram-negative, with composition of the fat acids and to the proteinic outline typical of the alteromonas family. This substance during the cellular growth produces a glycoprotein exopolymer composed of the 76-86% of proteins and to 8-14% of sugar, in base of the used means. This active substance have had use, previous to the invention, like a cosmetic humectant and emollient ingredient and like a substance with crioprotective property. Said active principle, of new and original application in the treatment of the diabetic foot, has important property that opposed the dryness of the skin typical of the diabetic patient. It gives, infact, the coesion between the spinous and germinativum stratum favouring the madding and the folding of the interkeratociti liquids, so as estimated through the compression studies of the isotherms and of the multilayer of the Langmuir balance. Moreover, said substance stimulates the growth of the human skin fibroblast in the tests in vitro without the growth of the keratinociti, so acting onto the micro-ulcerations of the skin to their first turning up and onto all the cute surface, from the knee to the foot. Moreover, the active principle given to the cited substance increases the formation of elastin and of collagen type I and type IV with increasing of the cute hydration of at least the 45% in the twelve subsequent hours in comparison with a sample of skin not treated or treated with cream with the only placebo effect. This substance is inserted in the wet fabric in a quantity of at least 1 mg/ml. To the fabric 1 is then added, without order of insertion to the fabric but with modality of charge and recharge following described, an exapeptide (10) from the alpha chain (known with trade "serilesine"). This peptide increases the adhesion of the cells, favours the cellular proliferation and betters the microcirculation such as it favours the angiogenesis. This active substance is added to the wet fabric 1 in quantity at least of 0,05 mg/ml. Also this last substance is never previous used for the use in pathology such that of the diabetic foot. Both these substances are previous used in the cosmetic field. So they do not present toxicity problems and they are not to be considered drugs to be prescribed with prescription. In particular they do not have, such the made tests has certified, cytotoxicity on human fibroblasts, cytotoxicity on keratinocity, they have no given toxicity prove in the tests of hemolysis, in the tests of genotoxicity, i.e. in the Ames tests, and they are not irritating as valuing with the het-cam for the valuation of the potential ocular irritation. The used substances in the described concentrations do not create irritation to the skin, sensitization phenomenon, ocular irritation and oral and skin toxicity. These substances 9 and 10 are moreover bound to the fabric 1 essentially for coulomb bond, being they with prevalent positive charge whereas the fabric has fibres with negative charge for own constitution. The substances 9 and 10 are mixed into microcapsules 11 soluble in water. The fabric 1 is then washed in water at 50°C. Ending this working the water is discharged and the fabric is wet with clean water to which is added a mordanting assistant 12, the Nylofixam PM (sold by Clariant) that has the function to bound the substances contained in the microcapsules 11 to the aminic group of the fabric 1, by means of the polarization that favours the union between the fabric 1 and the substances 9 and 10 into the microcapsules. The fixer 12 is then added in proportion of 4% of the weight of the fabric 1 to treat. Then are introduced in the bath the microcapsules 11 in the dose previous described and in total quantity of the 6% of the weight of the fabric. After ten minutes is added a cationic product 13, i.e. softenol 70 (sold by Lautex) that contributes also it to bound the microcapsules 11 with the fabric 1. The "lautex" is added in percentage of 2% of the weight of the fabric. After ninety minutes the bath is let out and the fabric 1 is centrifuged and dry, ready to be used. In the version for the domestic use the microcapsules 11 and the fixers 12 and 13 to the fabric 1 are sold in pre-dosed packaging, to can use the stocking 2, the pantyhose 3, the sock 4, the winding bandage 5, the bandage or plaster 6. To actuate the recharging of the active substances 9 and 10 to the fabric 1 for domestic three grams of substances 9 and 10 in microcapsules 11 are brought and they are dissolved into 300-500 ml. of water, after to have washed the used fabric 1, at a temperature inferior to 40°C. The pantyhose, or the sock or the other forms of the fabric 1 are then left in soaking for 15-20 minutes. These products are then dry in air. After this treatment the fabric 1 have an uniform distribution of the active principles. With pre-determined times are provided rechargings, also conserving the active principles effectiveness till the third days of use. The invented product conserves the active principles also after three washings. However, it is suggested the daily washing and the recharging after three days from the first use with the method above described. The simple application of a cream with active principles does not reach the useful results for the diabetic foot pathology such as the results obtained with the invention such as the friction of the foot with the conventional pantyhose creates, during the walk, frictions that take off the cream instead of makes it to absorb to the skin of the foot and neither the occlusive bandages with cream and gauzes are not to be used if no with the patient in bed. The invention is so to be used in the daily without constraints and/or changing to the style of life of the patient. The invention in the application in the form of application also winding bandage 5, cicatrizant bandage or plaster 6 have application also remedy for the bedsores and/or light wounds.. The cicatrizant action, the better of the micro-circulation and the effect on the derma determine a quick healing of these woods without collateral effects. The invention is illustrated in a merely indicative way in the drawings of sheets 1 and 2. In sheet 1 figure 1 is view of an example of production like a stocking. In the same table 1 the figure 2 is view of an application like a stock. Figure 3 is view of the version like a pantyhose. Figure 4 is view of the version of winding bandage with closed profile. Figure 5 is view of the version of bandage or plaster. In sheet 2 are illustrated some sequences of the recharging phase of the active principles of the invention. In detail figure 6 is view of the immersion phase. Figure 7 is view of the invention soaks in water with the active principles.

Claims (7)

  1. A fabric with active principles (1), said fabric consisting of lycra fibres and micro-fibres, characterized in that it has distributed along the fibres, as active principles, a glycoprotein (9) and a hexapeptide (10), wherein said active principles prevent and/or give the first cures to the diabetic foot.
  2. The fabric according to claim 1, in which said glycoprotein (9) is the Pseudoalteromonas ferment extract, synthesized by the bacteria Pseudoalteromonas Antarctica NF3, and said hexapeptide (10) is the hexapeptide from the alpha chain serilesine.
  3. The fabric according to anyone of claims 1-2, in which said active principles, glycoprotein (9) and hexapeptide (10), are mixed into microcapsules (11) soluble in water.
  4. The fabric according to anyone of the preceding claims, in which said active principles, glycoprotein (9) and hexapeptide (10), are bound to the fabric essentially for coulomb bonds.
  5. The fabric according to anyone of the preceding claims, said fabric having the production form of a stocking (2), of a pantyhose (3), of a sock (4), of a winding bandage with closer border (5) of a bandage or plaster (6) to realize a continuous and persistent contact with the skin of the diabetic patient.
  6. A method for recharging the active principles into a fabric according to anyone of claims 1-5, characterized in that the recharging or the first charging of the washed fabric is actuated bathing the fabric (1) with clean water to which is added a fixer, Nylofixan PM (12), in proportion of 4% of the weight of the fabric (1) to be treated, subsequently putting in the bath the microcapsules (11), containing the active principles (9) and (10), in a total quantity equal to 6% of the weight of the fabric, then, after ten minutes, a the cationic product Softenol 70 is added in percentage of 2% of the weight of the fabric and, after ninety minutes, the bath is discharged and the fabric (1) is centrifuged and dried.
  7. A method for recharging the active principles into a fabric according to anyone of claims 1-5, characterized in that it provides, for the recharging in domestic use, the use of three grams of the substances (9) and (10) into the microcapsules (11), dissolved into 300-500 ml of water at a temperature inferior to 40°C, and subsequent soaking of the fabric (1) for at least fifteen minutes.
EP06004931A 2005-03-11 2006-03-10 Fabric with active principles and relevant recharging method of the active principles Active EP1700947B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DE602006008679T DE602006008679D1 (en) 2005-03-11 2006-03-10 Tissue-loaded tissue, as well as the corresponding procedure for recharging the active ingredients

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT000140A ITBO20050140A1 (en) 2005-03-11 2005-03-11 FABRIC WITH ACTIVE PRINCIPLES AND RELATED METHOD OF RECHARGING ACTIVE INGREDIENTS

Publications (3)

Publication Number Publication Date
EP1700947A2 EP1700947A2 (en) 2006-09-13
EP1700947A3 EP1700947A3 (en) 2007-07-18
EP1700947B1 true EP1700947B1 (en) 2009-08-26

Family

ID=36581655

Family Applications (1)

Application Number Title Priority Date Filing Date
EP06004931A Active EP1700947B1 (en) 2005-03-11 2006-03-10 Fabric with active principles and relevant recharging method of the active principles

Country Status (5)

Country Link
EP (1) EP1700947B1 (en)
AT (1) ATE440994T1 (en)
DE (1) DE602006008679D1 (en)
ES (1) ES2332374T3 (en)
IT (1) ITBO20050140A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10149799B2 (en) 2010-03-25 2018-12-11 Sigvaris Ag Compression textiles
AU2015340458B2 (en) * 2014-10-31 2021-07-08 Lipotec, S.A.U. Cosmetic and/or pharmaceutical composition containing a bacterial extracellular product from pseudoalteromonas antarctica, and use thereof

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2336995B1 (en) * 2008-10-13 2011-02-09 Lipotec, S.A. COSMETIC OR DERMOPHARMACEUTICAL COMPOSITION FOR SKIN CARE, HAIR LEATHER AND NAILS.
EP2540263A1 (en) 2011-06-29 2013-01-02 Sigvaris Inc. Graduated compression garments

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1638494B1 (en) * 2003-07-02 2014-05-07 Invista Technologies S.à.r.l. Sleeve-like knitted structure for use as a castliner

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10149799B2 (en) 2010-03-25 2018-12-11 Sigvaris Ag Compression textiles
AU2015340458B2 (en) * 2014-10-31 2021-07-08 Lipotec, S.A.U. Cosmetic and/or pharmaceutical composition containing a bacterial extracellular product from pseudoalteromonas antarctica, and use thereof

Also Published As

Publication number Publication date
DE602006008679D1 (en) 2009-10-08
ATE440994T1 (en) 2009-09-15
EP1700947A3 (en) 2007-07-18
ES2332374T3 (en) 2010-02-03
ITBO20050140A1 (en) 2006-09-12
EP1700947A2 (en) 2006-09-13

Similar Documents

Publication Publication Date Title
US9220636B2 (en) Sock for treatment of foot and leg wounds, methods of use and manufacture
US10149799B2 (en) Compression textiles
US20140221948A1 (en) Hygienic or personal care article having a content of copper or copper ions
US10639469B2 (en) Sock for treatment of foot and leg wounds, methods of use and manufacture
JP2009523474A (en) Antiseptic alginate preparation
Haug et al. Coated textiles in the treatment of atopic dermatitis
EP1700947B1 (en) Fabric with active principles and relevant recharging method of the active principles
CN202932044U (en) Antibacterial deodorant stocking
Vachhrajani et al. Science of wound healing and dressing materials
US20090280151A1 (en) Fabric with active principles and relevant recharging method of the active principles
US7166307B1 (en) Herb medicine composition to be spread on sanitary napkin for female
CA2627223A1 (en) Wound-healing pharmaceutical compositions in the form of a sterile powder based on amino acids and sodium hyaluronate
WO2020144564A1 (en) Composition for the treatment of skin lesions and irritations
CN101003943A (en) Nano antibacterial cotton textile materials, and a series of commodity of sanitation
JPH1037070A (en) Antimicrobial fiber containing catechin of green tea component
KR101821965B1 (en) Functional stocking socks having an double fabric structure
CN103147271A (en) Nano antibiosis and bacteriostasis cotton textile material and products thereof
Heide et al. Antimicrobial-finished textile three-dimensional structures
CN1874748A (en) Textile and footwear products treated with sulfur
Shirvan et al. Allergies caused by textiles and their control
Bairagi et al. Textile structures for medical applications
EP2667904B1 (en) Compression stockings and tubes with bioactive agents for the treatment of venous insufficiency and varicose veins
KR200367929Y1 (en) Nano silver socks
Marinova THE EFFECT OF TOPICAL APPLICATION WITH OZOILE® AS A NOVEL METHOD IN THE COMPLEX TREATMENT OF SOFT TISSUE INFECTIONS AND CHRONIC WOUNDS.
CN101108209A (en) Traditional Chinese medicine for treating beriberi

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK YU

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK YU

17P Request for examination filed

Effective date: 20080116

17Q First examination report despatched

Effective date: 20080226

AKX Designation fees paid

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REF Corresponds to:

Ref document number: 602006008679

Country of ref document: DE

Date of ref document: 20091008

Kind code of ref document: P

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: BUGNION S.A.

LTIE Lt: invalidation of european patent or patent extension

Effective date: 20090826

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090826

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20091226

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090826

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090826

NLV1 Nl: lapsed or annulled due to failure to fulfill the requirements of art. 29p and 29m of the patents act
REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2332374

Country of ref document: ES

Kind code of ref document: T3

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090826

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090826

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090826

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090826

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20091126

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090826

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20091228

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090826

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090826

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090826

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090826

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090826

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090826

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20100527

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100331

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20091127

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100310

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100310

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100227

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090826

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 11

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20170222

Year of fee payment: 12

Ref country code: CH

Payment date: 20170227

Year of fee payment: 12

Ref country code: FR

Payment date: 20170221

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20170224

Year of fee payment: 12

Ref country code: AT

Payment date: 20170222

Year of fee payment: 12

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: ING. MARCO ZARDI C/O M. ZARDI AND CO. S.A., CH

Ref country code: CH

Ref legal event code: PUE

Owner name: HARMONIUM INVESTMENTS LIMITED, GB

Free format text: FORMER OWNER: LVM TECHNOLOGIES S.R.L., IT

Ref country code: CH

Ref legal event code: PUE

Owner name: LVM TECHNOLOGIES S.R.L., IT

Free format text: FORMER OWNER: RESTANI, MORENA, IT

REG Reference to a national code

Ref country code: DE

Ref legal event code: R082

Ref document number: 602006008679

Country of ref document: DE

Representative=s name: MOSER GOETZE & PARTNER PATENTANWAELTE MBB, DE

Ref country code: DE

Ref legal event code: R081

Ref document number: 602006008679

Country of ref document: DE

Owner name: HARMONIUM INVESTMENTS LTD., GB

Free format text: FORMER OWNERS: RESTANI, MORENA, CALDERATA DI RENO, IT; LENZI, LUCIO, VERGATO, IT

REG Reference to a national code

Ref country code: GB

Ref legal event code: 732E

Free format text: REGISTERED BETWEEN 20170921 AND 20170927

REG Reference to a national code

Ref country code: GB

Ref legal event code: 732E

Free format text: REGISTERED BETWEEN 20170928 AND 20171004

REG Reference to a national code

Ref country code: ES

Ref legal event code: PC2A

Owner name: LVM TECHNOLOGIES S.R.L.

Effective date: 20171113

REG Reference to a national code

Ref country code: ES

Ref legal event code: PC2A

Owner name: HARMONIUM INVESTMENTS LIMITED

Effective date: 20171205

REG Reference to a national code

Ref country code: FR

Ref legal event code: TP

Owner name: HARMONIUM INVESTMENTS LIMITED, GB

Effective date: 20171213

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 602006008679

Country of ref document: DE

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: AT

Ref legal event code: MM01

Ref document number: 440994

Country of ref document: AT

Kind code of ref document: T

Effective date: 20180310

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20180310

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20181002

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180310

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180331

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180331

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180310

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180331

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20190904

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180311

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20240325

Year of fee payment: 19